Guy Greiveldinger is the Head of Precision Medicine BD&L at Novartis where he is responsible for the negotiation of licensing, development and commercial agreements across the entire Novartis portfolio in the area of Precision Medicine. He works closely with technical and commercial as well as drug development teams during the evaluation of new diagnostic technologies. Since joining Novartis in 2009, he has been involved in several acquisitions and successfully negotiated numerous key transactions. Prior to joining Novartis, Guy has been Vice President Business Development & Licensing at Arpida, a Swiss Biotech company active in the field of anti-infectives. Besides having worked on several strategic business transactions during that time, he had assumed additional responsibilities as the lead for pre-launch activities for a hospital antibiotic including the set-up of commercial operations in the US. Guy has almost 20 years of experience in the biotechnology and pharmaceutical industry. He started his professional career as Head Marketing & Sales at Carbogen (a chemical development company, now part of the Dishman Group) where he was responsible for collaborations with leading biotech and pharmaceutical companies and was leading several new business initiatives. Guy holds a PhD in Organic Chemistry from the Swiss Federal Institute of Technology in Zürich (ETH Zürich), has been a Fulbright Research Fellow at the University of California in Berkeley and obtained an Executive MBA from the University of Rochester (Simon Business School).